Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study.
Giocanti-Aurégan A, García-Layana A, Peto T, Gentile B, Chi GC, Mirt M, Kosmas CE, Lambert J, Lanar S, Lewis HB, Holekamp NM. Giocanti-Aurégan A, et al. Patient Prefer Adherence. 2022 Mar 3;16:587-604. doi: 10.2147/PPA.S347713. eCollection 2022. Patient Prefer Adherence. 2022. PMID: 35264847 Free PMC article.
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators. Heier JS, et al. Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085502 Clinical Trial.
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Ranibizumab for neovascular age-related macular degeneration.
Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J. Hernandez-Pastor LJ, et al. Am J Health Syst Pharm. 2008 Oct 1;65(19):1805-14. doi: 10.2146/ajhp070342. Am J Health Syst Pharm. 2008. PMID: 18796421 Review.
The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age-related macular degeneration long-term treated in real world.
Llorente-González S, Hernandez M, González-Zamora J, Bilbao-Malavé V, Fernández-Robredo P, Saenz-de-Viteri M, Barrio-Barrio J, Rodríguez-Cid MJ, Donate J, Ascaso FJ, Gómez-Ramírez AM, Araiz J, Armadá F, Ruiz-Moreno Ó, Recalde S, García-Layana A; Spanish AMD group. Llorente-González S, et al. Acta Ophthalmol. 2022 Mar;100(2):e521-e531. doi: 10.1111/aos.14905. Epub 2021 Jun 4. Acta Ophthalmol. 2022. PMID: 34085771 Free article.
164 results